Attached files

file filename
EX-31.2 - EXHIBIT 31.2 - IMMUNIC, INC.vtl-123116xexhibit312.htm
EX-32.1 - EXHIBIT 32.1 - IMMUNIC, INC.vtl-123116xexhibit321.htm
EX-31.1 - EXHIBIT 31.1 - IMMUNIC, INC.vtl-123116xexhibit311.htm
EX-23.1 - EXHIBIT 23.1 - IMMUNIC, INC.vtl-123116xexhibit231.htm
EX-21.1 - EXHIBIT 21.1 - IMMUNIC, INC.vtl-123116xexhibit211.htm
10-K - 10-K - IMMUNIC, INC.vtl-123116x10k.htm


Exhibit 32.2
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE
SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report on Form 10-K of Vital Therapies, Inc. (the “Company”) for the period ended December 31, 2016, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Michael V. Swanson, as Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that to my knowledge:
1. the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2. the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
Date: March 7, 2017
/s/ Michael V. Swanson
 
Michael V. Swanson
 
Chief Financial Officer
 
(Principal Financial and Accounting Officer)
The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. § 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.